D-0040-2027 Class II Ongoing

Recalled by Houston Rx LLC — Houston, TX

FDA drug recall D-0040-2027 was initiated by Houston Rx LLC on Sep 25, 2026 and is designated Class II. Reason for recall: Lack of assurance of sterility. The recall status is ongoing. Affected quantity: 64 vials.

Recall details

Product Type
Drugs
Report Date
Oct 21, 2026
Initiation Date
Sep 25, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
64 vials

Product description

Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.

Reason for recall

Lack of assurance of sterility.

Distribution pattern

Nationwide in the USA.

Code information

Lot# TZN-080326-20/2-2, Beyond Use Date: 12/01/2026.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0040-2027
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0040-2027. Report a data issue: hello@regdatalab.com.